Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Socrates E Papapoulos

Showing results (11-20 of 79) with videos related to

Pageof 8
Sort By:
Best Practice & Research. Clinical Rheumatology|May 20, 2014
Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approachesNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Best Practice & Research. Clinical Endocrinology & Metabolism|November 30, 2014
Novel approaches to the treatment of osteoporosisNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Calcified Tissue International|March 28, 2016
Sclerostin Inhibition in the Management of OsteoporosisNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Nature Reviews. Endocrinology|September 6, 2018
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathwayNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Endocrine|February 20, 2016
From disease to treatment: from rare skeletal disorders to treatments for osteoporosisNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Best Practice & Research. Clinical Endocrinology & Metabolism|November 20, 2018
Paget's disease of boneNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Bone|May 25, 2010
Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studiesAndrea Giusti, Neveen A T Hamdy, Socrates E Papapoulos
Clinical Pharmacokinetics|June 4, 2005
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosisSerge C L M Cremers, Goonaseelan Pillai, Socrates E Papapoulos
Calcified Tissue International|August 3, 2023
The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal OsteoporosisAthanasios D Anastasilakis, Polyzois Makras, Stergios A Polyzos, et al.
Bone|October 16, 2016
Sclerostin deficiency in humansAntoon H van Lierop, Natasha M Appelman-Dijkstra, Socrates E Papapoulos
Pageof 8

Showing results (11-20 of 79) with videos related to

Sort By:
Pageof 8
Best Practice & Research. Clinical Rheumatology|May 20, 2014
Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approachesNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Best Practice & Research. Clinical Endocrinology & Metabolism|November 30, 2014
Novel approaches to the treatment of osteoporosisNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Calcified Tissue International|March 28, 2016
Sclerostin Inhibition in the Management of OsteoporosisNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Nature Reviews. Endocrinology|September 6, 2018
Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathwayNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Endocrine|February 20, 2016
From disease to treatment: from rare skeletal disorders to treatments for osteoporosisNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Best Practice & Research. Clinical Endocrinology & Metabolism|November 20, 2018
Paget's disease of boneNatasha M Appelman-Dijkstra, Socrates E Papapoulos
Bone|May 25, 2010
Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studiesAndrea Giusti, Neveen A T Hamdy, Socrates E Papapoulos
Clinical Pharmacokinetics|June 4, 2005
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosisSerge C L M Cremers, Goonaseelan Pillai, Socrates E Papapoulos
Calcified Tissue International|August 3, 2023
The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal OsteoporosisAthanasios D Anastasilakis, Polyzois Makras, Stergios A Polyzos, et al.
Bone|October 16, 2016
Sclerostin deficiency in humansAntoon H van Lierop, Natasha M Appelman-Dijkstra, Socrates E Papapoulos
Pageof 8